Post by HAYA Therapeutics

✈️ Heading to San Diego for the BIO International Convention 2026? We are pleased to share that HAYA’s CBO, Richard J. Law, will be a featured panelist for the session, “Smart Science, Smart Deals: How AI Platforms are Transforming Drug Discovery Deals,” at #BIO2026. As AI becomes an industry baseline, the strategic focus for business development has shifted: the priority now is true biological differentiation and structuring transactions that accurately reflect a platform's long-term value. What differentiates HAYA in this AI era?   The current biotech landscape has built powerful computational engines designed to optimize, predict, and design molecules. However, the vast majority of these platforms are competing within the same narrow spotlight—the 2% of the human genome that codes for proteins. HAYA operates in the remaining 98%. Our proprietary, AI-powered platform maps and translates the Regulatory Genome to advance RNA-guided precision therapeutics designed to reprogram cell states and tackle causal disease biology at its roots. We look forward to discussing the evolving landscape of AI-enabled drug discovery with peers and partners, and sharing insights on how early partnering approaches can drive company value and therapeutic potential. 🤝   Join the Breakout Session:  Date: June 24th, 2026  Time: 3:00–4:00 PM  Location: San Diego Convention Center, Room 30DE Learn more: https://lnkd.in/dfkk5iF7  If you are attending #BIO2026 and are looking to explore platform partnerships, let’s schedule a time to connect. 🚀 #BIO2026 #BusinessDevelopment #AIBiotech #PlatformTherapeutics #StrategicPartnerships #RegulatoryGenome #CorporateDevelopment #ValueCreation